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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
 The use of budesonide/formoterol or extrafine beclometasone/formoterol in a single inhaler 
as maintenance and reliever therapy (MART) is effective and reduce the risk of 
exacerbations in uncontrolled asthmatics. 
 There are only two dry powder inhalers (DPI) with indication for MART therapy.   
WHAT THIS STUDY ADDS 
 Extrafine Foster® NEXThaler® DPI is suitable for MART approach, providing a valuable choice 
for asthmatic patients preferring DPIs instead of pMDIs. The reliever effect of Foster® 
NEXThaler® DPI is comparable to that of extrafine Foster® pMDI.  
 
ABSTRACT 
Aim 
To demonstrate the non-inferiority of extrafine beclomethasone/formoterol Fumarate (BDP/FF) dry 
powder inhaler (DPI) vs extrafine BDP/FF pressurised metered dose inhaler (pMDI) (Foster® 100/6 μg 
NEXThaler® and pMDI, respectively) in the onset of reliever effect after methacholine induced 
bronchospasm in asthmatic patients, evaluated in terms of FEV1 at 5 min post-dose. The DPI 
provides an alternative device option for patients who cannot use a pMDI properly during an acute 
asthma attack. 
Methods 
Sixty-five patients received one inhalation of BDP/FF DPI, BDP/FF pMDI or placebo after 
methacholine challenge, according to a double-blind, double-dummy, cross-over design. Lung 
function and Borg dyspnoea score were assessed up to 30 min post-dose.  
Results 
FEV1 adjusted mean difference between BDP/FF DPI and BDP/FF pMDI at 5 min post-dose was 2 ml 
(95% CI: -0.060; 0.065). A similar result was observed at the other time points. Median time to 85% 
recovery in FEV1 was 8 min for BDP/FF DPI, 7.5 min for BDP/FF pMDI and 28 min for placebo (p = 
0.554 DPI vs pMDI). 
The Borg score improved after treatment with both BDP/FF DPI and pMDI and the effect was greater 
than after placebo. Median time to reach 50% recovery was 4.2 min for BDP/FF DPI, 4.0 min for 
BDP/FF pMDI and 10.0 min for placebo (p = 0.609 DPI vs pMDI). 
Conclusions 
Extrafine Foster® NEXThaler®, a flow independent DPI, is comparable to extrafine Foster® pMDI 
when administered as reliever therapy after methacholine challenge, thus supporting the 
Maintenance And Reliever Therapy (MART) approach also with NEXThaler®. 
 
Trial registration number: ClinicalTrials.gov Identifier NCT03108534, EudraCT number 2016-003672-
47 
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1. INTRODUCTION 
Despite effective pharmacological treatments currently available for asthma, many patients are still 
poorly controlled (1). The use of a combination inhaler containing inhaled corticosteroid (ICS), such 
as budesonide or beclometasone dipropionate, and the long-acting β agonist (LABA) formoterol as 
both maintenance and relief therapy (MART) has been recommended to optimise ICS/LABA therapy 
in uncontrolled asthma (2). The effectiveness of this regime is thought to be the result of early 
intervention with rapid increases in ICS dose at the first symptoms, together with rapid symptom 
relief by virtue of the fast onset of action of formoterol (3). In fact, it has been shown that if a fast 
onset ICS/LABA is administered as «maintenance and reliever» at the first evidence of asthma 
worsening, it is possible to taper the inflammation as soon as it starts, thus preventing the 
development of the asthma exacerbation (4). Moreover, the effect on symptoms of a MART 
approach may significantly postpone the occurrence of exacerbations, thus reducing the yearly rate, 
as shown in a randomized clinical trial comparing the MART use of a low dose of extrafine 
formulation BDF/FF vs. SABA as rescue medication plus regular ICS/LABA intake (5). Prevention of 
asthma exacerbations is recognized in all current asthma guidelines as an important component of 
treatment because it results in a substantial reduction in work productivity and school or university 
attendance and represent the greatest cost for health-care systems. Finally, MART posology 
effectively enforces ICS adherence by linking use to reliever therapy with formoterol and is intuitive 
for patients to use on a flexible basis. 
 The fixed combination of extrafine formulation beclometasone dipropionate and formoterol 
fumarate (BDP/FF) (Foster®, Chiesi, Parma, Italy) was the first registered pMDI for the MART 
approach in asthma. A single dose of BDP/FF pMDI showed a fast  onset of action, similar to that of 
salbutamol, in the methacholine-induced bronchospasm model (6). Furthermore, a one-year study 
investigating the MART regime with BDP/FF pMDI demonstrated a prolonged time to first severe 
exacerbation and reduced rate of severe exacerbations in uncontrolled asthma patients along with a 
lower need to receive courses of systemic corticosteroids (5).  
To provide an additional delivery device option, a DPI, the NEXThaler®, containing the same 
extrafine formulation active ingredients of Foster® pMDI (100 μg of BDP and 6 μg of FF) has been 
developed (7). It is well established that some asthma patients cannot properly operate pMDI 
devices, or prefer to use a DPI (8). For these patients, Foster® NEXThaler® provides an alternative 
option in clinical practice, but its effectiveness in the MART approach has not been established.  The 
NEXThaler® is a multidose breath-actuated DPI, which is activated at an average inspiratory flow of 
35 L/min (9)(10). Flow independency in the drug delivery from NEXThaler® has been demonstrated 
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for both BDP and FF at different inspiratory flows ranging from 30 to 90 L/min, supporting the utility 
and effectiveness of the inhaler in patients with different degrees of lung function impairment and 
disease control. Considering the inspiratory flow independency for the DPI activation and that both 
pMDI and DPI contain the same active components, we hypothesized that there would be no 
differences between the two devices in terms of bronchodilation capacity to reverse acute 
bronchoconstriction, for example induced by methacholine. 
 In order to validate the potential use of Foster® NEXThaler® for the MART approach, it is 
necessary to evaluate whether its administration provides a quick onset of efficacy during acute 
severe bronchospasm. Therefore, we have compared the onset of bronchodilator action of the 
Foster® NEXThaler® with the pMDI using methacholine induced bronchoconstriction, which is a 
widely used and representative model of bronchoconstriction and a well-accepted bioassay for 
bronchodilator efficacy in asthma.  
2. METHODS 
2.1 Patients 
Patients aged between 18 and 60 years inclusive, with a diagnosis of persistent asthma for at least 6 
months were recruited in the trial and were required to fulfil the following criteria at study entry: 
non-smokers or ex-smokers, pre-bronchodilator FEV1 of at least 65% of predicted value and at least 
1.5 L, a positive response to methacholine challenge test (defined as a PD20 FEV1 ≤ 1 mg) and stable 
treatment with low-medium doses of ICS or ICS plus LABA combination as per current GINA 
guidelines (2).  
Patients were excluded from the study if they had experienced an asthma exacerbation in the 
previous 4 weeks or if they had any clinically relevant and uncontrolled concomitant disease. 
Pregnant or breastfeeding women were also excluded from the study participation.  
Non-permitted concomitant medications included systemic corticosteroids, leukotriene modifiers, 
anti-IgE antibodies, antihistamines, anticholinergic drugs and beta-blockers. Patients could remain 
on their previous treatment with ICS or ICS plus LABA combination, provided that LABA was withheld 
in the 48 hours before each study visit. Salbutamol was also allowed as rescue medication, with a 
required washout of at least 8 hours before any spirometric measurements.  
Patients were carefully trained with placebo inhalers to the use of both pMDI and DPI devices. 
The study was conducted in 4 clinical sites in United Kingdom, after approval from an independent 
Ethics Committee (North West - Liverpool Central Research Ethics Committee). The study was 
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performed in accordance with Good Clinical Practice, the Declaration of Helsinki and all applicable 
regulations. Written informed consent form was obtained from all study participants.  
2.2 Study design 
This was a randomised, double blind, double dummy, active treatment and placebo controlled, 3-
way crossover study. The study design is shown in Figure 1. A screening visit (V0) was performed to 
verify inclusion and exclusion criteria. During this visit, patients taking ICS/LABA fixed combinations 
were switched to the free combination of the same ICS and LABA, administered as separate inhalers, 
in order to allow the required washout from LABA prior to each visit. Treatment with ICS was 
maintained for the overall duration of the run-in and washout periods. Eligible patients were 
randomised and attended the clinical site for 3 treatment visits (V1 - V3), each separated by a 5 to 21 
days washout period.  
At each treatment visit, a baseline FEV1 was measured followed by a methacholine challenge test. To 
minimise variability between treatment days, FEV1 values before treatment visits had to be within ± 
15% of value at visit 1. During the challenge, performed using the "5-breath dosimetric method", 
increasing doubling doses of methacholine were administered to the patients until a decrease in 
FEV1 between 30% and 45% of the baseline value was observed. In case the level of dyspnoea 
became too severe or the decrease in FEV1 exceeded the 45% of baseline value, patients were 
immediately treated with salbutamol as reliever medication and discontinued from the study. 
Patients who reached the target-induced bronchoconstriction were treated with the study drug 
within 1 minute from the end of the provocation test, according to the randomisation list. The 
following treatments were administered: 1 inhalation of extrafine formulation BDP/FF 100/6 µg as 
DPI NEXThaler® (Foster® NEXThaler® 100/6 µg) or 1 inhalation of extrafine formulation BDP/FF 
100/6 µg as pMDI (Foster® 100/6 µg pMDI) or 1 inhalation with placebo, all appropriately blinded 
with another inhalation of placebo, in a double-dummy fashion. The two active drugs contained 
exactly the same combination of ICS (BDP) and LABA (FF), but were administered with a different 
formulation and device (i.e. dry powder via DPI NEXThaler® and solution via pMDI).  
The double-dummy technique was used to ensure blinding, so all patients inhaled from both types of 
inhaler devices. Half of the patients took Foster® NEXThaler® 100/6 first, the other half Foster® 
100/6 pMDI.   
FEV1 and level of dyspnoea, assessed with the Borg scale, were measured before the methacholine 
challenge test (FEV1 only), at the end of the challenge (PD30) and at 1, 3 (Borg scale only), 5, 10, 20 
and 30 minutes after study drug intake.  
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2.3 Study procedures  
FEV1 was measured with Pneumotrac 6800 (Vitalograph Ltd, Bucks, UK) according to the ATS/ERS 
recommendations (11) and the spirometry curves were centrally analysed. The highest value taken 
from 2 (during methacholine challenge test) or 3 (for post-dose time points) technically satisfactory 
attempts was recorded and used in the analysis. In order to avoid unnecessary discomfort for the 
patients due to the exhalation until the residual volume, each effort was terminated after 2 sec of 
exhalation (12).  
The 10-point Borg scale was used to provide a measure of the patient's perception of dyspnoea (13), 
with 0 indicating no appreciable breathlessness and 10 indicating the maximal tolerable sensation. 
The value at the end of the bronchoprovocation test was considered as the baseline value for 
dyspnoea assessments.  
Methacholine challenge test was performed with Marcos Mefar MB3 dosimeter and MB2 nebuliser 
(Air Liquide Medical Systems, Italy) according to the ATS recommendations (12); the same source of 
pre-diluted vials of methacholine chloride solution was used by all clinical sites (Stockport 
Pharmaceuticals). Saline solution was inhaled first, followed by a post-saline FEV1, which was used as 
baseline value for lung functions assessments. Methacholine was administered at increasing 
concentrations in order to obtain the cumulative doses ranging from 0.0028 to 2.8772 mg. FEV1 
measurements after each dose of methacholine were obtained in duplicate.  
2.4 Statistical Methods 
The primary objective of the study was to demonstrate the non-inferiority of BDP/FF 100/6 DPI vs 
BDP/FF 100/6 pMDI on the onset of relief from methacholine-induced bronchospasm in terms of 
change in FEV1 (L) from baseline to 5 minutes after study drug intake. The non-inferiority rather than 
the equivalence approach was chosen in order to demonstrate that BDP/FF DPI has a reliever effect 
that is at least good as compared to BDP/FF pMDI, which is already approved in clinical practice for 
the MART indication.  
Secondary endpoints included: change in FEV1 (L) from baseline to all other time-points after study 
drug intake, time to recovery in FEV1 (defined as the return to 85% of the baseline FEV1 value), FEV1 
AUC0-10min normalised by time, change in the Borg scale from the end of methacholine challenge test 
to all time-points after drug intake and time to recovery in the Borg scale (defined as 50% decrease 
from the post-methacholine value).  
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Safety and tolerability were assessed by analysis of Adverse Events (AEs) and vital signs. 
A sample size of 54 evaluable subjects provided 86% power for non-inferiority testing of BDP/FF 
100/6 DPI vs BDP/FF 100/6 pMDI, based on the change in FEV1 (L) from baseline to 5 minutes after 
study drug intake, assuming a non-inferiority margin of -0.120 L between the two treatments, a 
within-subject standard deviation of 0.20 L and at a two-sided alpha error set at 0.05. Assuming a 
drop-out rate of 10%, approximately 60 subjects were to be randomized. All randomised subjects 
who completed at least one treatment period were included in the Intention To Treat (ITT) 
Population.  
Change in FEV1 from baseline to 5 minutes after study drug intake was analysed using an analysis of 
covariance (ANCOVA) model including treatment, period and subject as fixed effects and FEV1 
baseline and FEV1 at the end of challenge as covariates. The adjusted means in each treatment group 
and the adjusted mean differences between treatments were estimated by the model with their 
95% confidence intervals (CIs). 
Change in FEV1 (L) from baseline to all other time-points and FEV1 AUC0-10min normalised by time 
were analysed using the same ANCOVA model as for the primary endpoint.  
Change in the Borg scale from the end of methacholine challenge test to all time-points after drug 
intake was analysed using an ANCOVA model including treatment, period and subject as fixed 
effects, Borg scale baseline and Borg scale at the end of challenge as covariates.  
Time to recovery variables were analysed by using the Kaplan-Meier method. This provided plots 
and estimates of median times to recovery and pertinent 95% Interquartile Range (IQR). For subjects 
who recovered within 30 minutes from study drug intake the exact time to recovery was estimated 
by a linear interpolation between the last time point before recovery and the first time point 
showing recovery. For subjects who did not recover within 30 minutes, the time to recovery was 
extrapolated by the trend observed in the first 30 minutes. In the event the extrapolated time to 
recovery was greater than 50 minutes, it was conventionally set at 50 minutes. Comparison between 
treatment groups and p-value were estimated by Cox model.  
AEs, Serious AEs (SAEs) and AEs leading to discontinuations were presented descriptively.  
All efficacy analyses were performed on the Intention to Treat (ITT) population, defined as all 
randomised patients who received at least one dose of study treatment and with at least one 
available evaluation of efficacy after the baseline. Analysis on primary endpoint was also repeated 
on the Per Protocol population, (ITT population without any major protocol violation). Safety 
analyses were performed on the Safety population consisting of all randomised subjects who 
received at least one dose of study treatment after randomisation. 
Data were analysed using SAS Version 9.4 for Windows.  
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3. RESULTS 
Patients' baseline characteristics are reported in Table 1. Sixty-five subjects were randomised to 
treatment. Five subjects did not complete the treatment periods for the following reasons (1 subject 
each): adverse event, baseline FEV1 < 65% of predicted value, fall in FEV1 of at least 30% not reached, 
excessive reaction to methacholine with fall in FEV1 > 45% and lost to follow-up.  
3.1 Methacholine challenge  
Baseline FEV1 measurements (P1) and measurements at the end of the challenge (P2) were similar 
between all the treatments (Table 2). The FEV1 at the end of the provocation dropped to 
approximately 66% of P1. 
3.2 FEV1    
Both BDP/FF formulations caused rapid FEV1 increases; there was an FEV1 improvement at 5 minutes 
post dose, which was 224 mL and 222 mL higher than placebo with BDP/FF DPI and BDP/FF pMDI 
respectively, demonstrating a rapid relief of bronchoconstriction with both formulations (Figure 2). 
Significant differences were observed between active treatments and placebo at all time points. At 5 
minutes post-dose, the adjusted mean difference between BDP/FF DPI and BDP/FF pMDI was 2 ml 
(95% CI: -0.060; 0.065), with similarity between the effects of these BDP/FF formulations also 
observed at other time points.  
The adjusted mean FEV1 AUC0-10min normalised by time were 2.26 L, 2.25 L and 2.07 L for BDP/FF DPI, 
BDP/FF pMDI and placebo, respectively, with no differences between BDP/FF DPI and BDP/FF pMDI; 
both actives being  superior to placebo (p < 0.001).  
The recovery with BDP/FF DPI was fast (median time of 8 minutes), similar to BDP/FF pMDI (median 
time of 7.5 minutes; p = 0.554), and much shorter than placebo (28 minutes; p < 0.0001) (Figure 3). 
At 5 minutes post-dose, the mean FEV1 value was greater than 82% of baseline value after inhalation 
of the active treatments and lower with placebo (74%).  
3.3 Borg dyspnoea scale  
The mean Borg dyspnoea score was below 0.5 before the methacholine challenge test (Figure 4, P1) 
and increased (worsening) up to more than 4 at the maximum methacholine-induced 
bronchoconstriction in all treatment periods (Figure 4, P2). After dosing, an improvement in the 
mean Borg dyspnoea score occurred after administration of all treatments, with a greater effect 
observed with the two active drugs as compared to placebo (47.3% improvement with BDP/FF DPI, 
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44.1% with BDP/FF pMDI and 34.2% with placebo at the 5 minutes post-dose time point). Median 
time to recovery, expressed as the time needed for the Borg dyspnoea score to reach 50% of 
recovery, was 4.2 minutes with BDP/FF DPI, which was similar to BDP/FF pMDI (4.0 minutes, p = 
0.609), and significantly shorter than placebo (10.0 minutes; p = 0.042).  
3.4 Adverse events 
No serious or severe adverse events (AEs) or adverse drug reactions (ADRs) were reported. The 
frequency of the reported AEs was comparable among treatments (4 patients reported AEs after 
intake of BDP/FF DPI and BDP/FF pMDI and 5 patients after intake of placebo).  The most commonly 
reported AEs were nasopharyngitis (1 after BDP/FF DPI and 1 after BDP/FF pMDI) and cough (2 after 
BDP/FF DPI). Other AEs, occurring in no more than 1 patient, were: urinary tract infection after 
BDP/FF DPI, seasonal allergy, chest pain and headache after BDP/FF pMDI, lower respiratory tract 
infection, arthropod bite, limb injury, dizziness, oropharyngeal pain and urticaria after placebo. Only 
one AE was considered as possibly related to the study drug (oropharyngeal pain), while another AE 
lead to the permanent discontinuation of the study drug (lower respiratory tract infection). Both AEs 
occurred after administration of placebo.  
4. DISCUSSION 
The results of the present study showed that BDP/FF extrafine formulation DPI was non-inferior to 
BDP/FF extrafine formulation pMDI in the reliever effect as measured by 5-minute post-dose FEV1. 
The FEV1 increase was 224 and 222 mL higher than placebo with BDP/FF DPI and pMDI, respectively, 
at 5 minutes post dose. Other lung function measures and the Borg dyspnoea score as secondary 
endpoints showed similar results with the two formulations, confirming that DPI and pMDI are 
similar when used as a reliever therapy. 
In terms of time to recovery of lung function, expressed as the median time to return to 85% of the 
baseline value, BDP/FF 100/6 DPI and BDP/FF 100/6 pMDI were again comparable, with times to 
recovery of 8 and 7.5 minutes, respectively, confirming rapid reliever effect.  
The FEV1 improvements exceed the threshold accepted for significant bronchodilator reversibility 
(14), and were observed rapidly (within 5 minutes). Furthermore, the FEV1 improvements at 5 
minutes were associated with greater improvements in the Borg dyspnoea rating, indicating that the 
bronchodilation was also perceived by patients. Early patient withdrawals induced a slight imbalance 
in the number of patients per sequence. The only effect of this imbalance was a small loss of 
efficiency in statistical testing. However, the potential “sequence effect” was already accounted for 
by the “subject effect” included in all statistical models. Moreover, a wash-out period between 
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treatments of appropriate duration (minimum 5 days and maximum 21 days) excluded by design any 
carry-over effect. 
Overall, the results demonstrate that in asthmatic patients subjected to methacholine-induced 
bronchoconstriction to mimic an asthma attack, the degree of bronchodilation achieved with BDP/FF 
NEXThaler® was practically identical to that achieved with BDP/FF pMDI, both in terms of magnitude 
and onset of action.  
In this study, the mean drop in FEV1 after the use of methacholine was greater than 30% from 
baseline values, with most patients demonstrating a post-methacholine FEV1 lower than 2L, 
representing clinically relevant bronchoconstriction as might occur in acute asthma. This model has 
previously been used to demonstrate the similarity of BDP/FF extrafine formulation pMDI compared 
to salbutamol. In this previous study (hereafter mentioned as MART1 trial) (6), it was observed that 
the median time to FEV1 recovery was <5 minutes for both treatments, while in the current study 
this was approximately 7-8 minutes for BDP/FF administered by pMDI or DPI. A relatively slower 
time to recover was observed for BDP/FF pMDI in the current study but also the median time to 
recovery with placebo was also slower in the current study (28.2 minutes versus 21.4 minutes). The 
overall magnitude of bronchoconstriction achieved (P2 time point in Figure 2) was similar in both 
studies (approximately 65% of P1 measurement, Figure 2). Considering that the same bronchial 
challenge protocol was used in both studies, with similar effects at P2, then it appears that the 
current study involved subjects with a naturally longer time to recovery, highlighted in the 
comparison of BDP/FF pMDI and placebo results between studies. It should be noted that the 
asthma population previously studied in the MART1 trial was less severe in terms of FEV1 % 
predicted than in the current study (92 % versus 80 % respectively).  It is possible that a thickened 
mucosa and submucosa and altered airway secretions have affected the availability of the β2-
agonists to their related receptors, delaying the bronchodilator response  (15). Furthermore, in the 
current study only 38 % (vs 73% in the previous study) of asthma patients were in previous 
treatment with ICS plus LABA, potentially suggesting a lower level of control on the airway tone by 
the LABA component in the enrolled population. While caution should be exercised when comparing 
across studies, differences in the study population characteristics may have contributed to the 
differences observed.  
An indirect comparison between formoterol in the DPI formulation in the present study and 
salbutamol in MART1 study is difficult to perform. However, the results of the present study are in 
agreement with other studies that have evaluated the acute effects of bronchodilators using this 
model (16) (17).  Politiek et al. (17) found that the geometric mean time for FEV1 to return to 85% of 
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baseline was 7.2 minutes with formoterol DPI, 6.5 min with salbutamol and 34.7 minutes with 
placebo. Beach et al. (16), when comparing the speed of action of single doses of formoterol and 
salbutamol in DPI formulation in reversing methacholine induced bronchoconstriction, reported that 
both salbutamol and formoterol produced bronchodilator effects within 2 min after inhalation and 
reached a maximum after 10 min. Another study (18) with the same model but with specific airway 
conductance (sGaw) as primary endpoint, as sGaw can be a more sensitive index of changes in 
airway calibre than FEV1, concluded that both salbutamol and formoterol have very rapid onset of 
action with salbutamol slightly faster.  In terms of perception of the relief of dyspnoea assessed by 
the Borg scale, in the present study, the median time to 50% recovery was 4.25 min in agreement 
with the obtained value of 5 min for BDP/FF pMDI and 3.5 min for salbutamol in the MART1 study. 
This indicates that the administration of BDP/FF pMDI, BDP/FF DPI and salbutamol had comparable 
effects in terms of dyspnoea relief after induced bronchoconstriction. 
BDP/FF NEXThaler® is the only extrafine formulation DPI designed to provide physicians and patients 
with an alternative easy to use delivery system, especially for those patients preferring DPIs or 
experiencing poor coordination with pMDIs. The Breath Actuated Mechanism (BAM), that is 
activated at an average inspiratory flow rate of 35 L/min (9)(10), triggers the counting only of 
effective inhalations as compared to other available DPIs such us Turbohaler® and Ellipta® devices. 
The NEXThaler® is a medium resistance device and is comparable in that respect to the marketed 
Turbohaler® device, already approved as Symbicort Turbohaler® for MART posology and it  requires 
an inspiratory flow rate of 54 L/min to generate a drop of 4 kPa, that is lower than that of other 
device not used for MART posology like Ellipta® (74 L/min) (19).  
In another published study (20), the in vitro characteristics of NEXThaler® were compared to Diskus® 
and Turbohaler® dry powder at flow rates between 30 L/min and 100 L/min, relevant to the target 
population for MART, showing to deliver consistent delivery performance across different flow rates 
and regardless the applied inspiratory flow.  
Other data (10) evaluated the inspiratory profile of the NEXThaler® device in adult asthma patients 
with different level of asthma control and therefore all patients were able to activate and use the 
device effectively.  
In summary, this study shows that the bronchodilator effect of Foster® 100/6 NEXThaler® extrafine 
formulation occurs rapidly and is non-inferior to Foster® 100/6 extrafine formulation pMDI in 
reversing methacholine-induced severe bronchoconstriction as a model of acute severe 
bronchospasm. The results support the suitability of extrafine formulation BDP/FF 100/6 DPI 
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NEXThaler® for the MART approach. 
 
ACKNOWLEDGMENTS: 
The clinical trial was sponsored by Chiesi Farmaceutici S.p.A.. 
D.Singh, F. van den Berg, B. Leaker and B. Lipworth were the principal investigators of the 4 clinical 
sites where the clinical trial was performed. D. Singh also acted as coordinating investigator. S. 
Jabbal was the co-investigator at the Scottish Centre for Respiratory Research in Dundee. M. Corradi, 
S. Collarini, V. Mongelli, L. Santoro, A. Piccinno and B. Lipworth were involved in the study design 
and results interpretation. S. Biondaro and L. Santoro were involved in data collection and analysis 
and are responsible for the integrity of the data and accuracy of the data analysis. SGS Belgium NV 
(Antwerp, Belgium) was responsible for monitoring, data management, statistics, pharmacovigilance 
and medical writing during the trial. Biomedical Systems (Brussels, Belgium) was responsible for 
central collection and over-reading of the lung function data. 
The manuscript was written by M. Corradi, S. Collarini, L. Santoro and A. Piccinno and reviewed and 
approved by all the authors.  
 
COMPETING INTERESTS: 
D. Singh has received sponsorship to attend international meetings, honoraria for lecturing or 
attending advisory boards and research grants from various pharmaceutical companies including 
Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, 
Johnson and Johnson, Mundipharma, Novartis, Peptinnovate Pfizer, Pulmatrix, Skypharma, Teva, 
Therevance and Verona. 
F. van den Berg has no conflict of interests to declare.  
B. Leaker has received investigator fees from Chiesi for this and other studies; similar investigator 
fees were also received from Regeneron Pharmaceuticals, Astra Zeneca, Afimmune, Verona, Moerae 
Matrix and Hemay Pharmaceutical Pty. Ltd in the last 12 months.  
M. Corradi has received grants and honoraria for lectures from Chiesi. 
S. Jabbal has received personal fees and non-financial support from Chiesi, personal fees and non-
financial support from Pfizer, non-financial support and other from Napp, personal fees and non-
 
This article is protected by copyright. All rights reserved. 
financial support from AstraZeneca, non-financial support from Teva, non-financial support from 
Meda, personal fees from Boehringer Ingelheim, outside the submitted work. 
S. Collarini, V. Mongelli, L. Santoro, A. Piccinno and S. Biondaro are full-time employees at Chiesi 
Farmaceutici S.p.A.. 
B. Lipworth and the Scottish Centre for Respiratory Research have received funding in the form of 
consultancy, advisory boards, research, travel grants, equipment or giving talks from Chiesi 
Farmaceutici S.p.A., Boerhinger Ingelheim, Teva, Meda Pharma, Mylan, AstraZeneca, Dr Reddys, 
Cipla, Lupin, Genentech, Sanofi, Jansen, GSK, Novartis, Vectura, Glenmark.  
  
 
This article is protected by copyright. All rights reserved. 
REFERENCES 
1.  Magnoni MS, Latorre M, Bettoncelli G, Sanchez-Herrero MG, Lopez A, Calvo E, et al. Asthma 
control in primary care: the results of an observational cross-sectional study in Italy and 
Spain. Vol. 10, World Allergy Organization Journal. 2017. p. 13.  
2.  GINA. Global strategy for asthma management and prevention (GINA 2017). Glob Initiat 
Asthma. 2017;147.  
3.  Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for 
adults and children with asthma. Vol. 2010, Cochrane Database of Systematic Reviews. 2010.  
4.  Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer C-A, O ’byrne PM, et al. 
Exacerbations of Asthma A Descriptive Study of 425 Severe Exacerbations. Am J Respir Crit 
Care Med [Internet]. 1999 [cited 2018 May 17];160:594–9. Available from: 
https://www.atsjournals.org/doi/pdf/10.1164/ajrccm.160.2.9811100 
5.  Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, et al. 
Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: A 
double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(1):23–31.  
6.  Singh D, Corradi M, Bindi E, Baronio R, Petruzzelli S, Paggiaro P. Relief of methacholine-
induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in 
comparison with salbutamol in asthma. Pulm Pharmacol Ther. 2012;25(5):392–8.  
7.  Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine 
beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler®) or pMDI and 
beclomethasone monotherapy for maintenance of asthma control in adult patients: A 
randomised, double-blind trial. Pulm Pharmacol Ther. 2015;30:121–7.  
8. Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert 
Opin Drug Deliv. 2009 Jan;6(1):91-102. doi: 10.1517/17425240802637862 . 
9.  Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R, et al. NEXThaler, an 
innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone 
and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 
2014;11(9):1497–506.  
10.  Scuri M, Alfieri V, Giorgio A, Pisi R, Ferrari F, Taverna MC, et al. Measurement of the 
inhalation profile through a novel dry powder inhaler (NEXThaler®) in asthmatic patients 
using acoustic monitoring. Am J Respir Crit Care Med. 2013;187:A1931.  
 
This article is protected by copyright. All rights reserved. 
11.  Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of 
spirometry. Vol. 26, European Respiratory Journal. 2005. p. 319–38.  
12.  American Thoracic Society Guidelines for Methacholine and Exercise Challenge Testing — 
1999. Am J Respir Crit Care Med. 1999;161(10):309–29.  
13.  Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg scale in assessing the 
degree of dyspnea in patients with COPD and asthma. J Emerg Nurs. 2000;26(3):216–22.  
14.  Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative 
strategies for lung function tests. Eur Respir J. 2005;26:948–68.  
15.  Polosa R, Prosperini G, Magri S, Ciamarra I, Pagano C, Paolino G, et al. Bronchodilator 
response to salbutamol after spontaneous recovery from nonspecific bronchial provocation 
tests in asthma. Eur Respir J. 1998;11(5):1086–90.  
16.  Beach JR, Bromly CL, Avery AJ, Reid RWEC, Walters EH, Hendrick DJ. Speeds of action of single 
doses of formoterol and salbutamol compared with placebo in reversing methacholine-
induced bronchoconstriction. Pulm Pharmacol. 1996;9(4):245–9.  
17.  Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in 
methacholine- induced severe bronchoconstriction. Eur Respir J. 1999;13(5):988–92.  
18.  Van Noord JA, Smeets JJ, Maesen FPV. A comparison of the onset of action of salbutamol and 
formoterol in reversing methacholine-induced bronchoconstriction. Respir Med. 1998;  
19.  Krüger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder 
inhalers (DPI). Eur Respir J. 2014;44(Suppl 58).  
20.  Buttini F, Brambilla G, Copelli D, Sisti V, Balducci AG, Bettini R, et al. Effect of Flow Rate on In 
Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and 
Turbohaler(®) Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv. 2016;29(2):167–78.  
 
  
 
This article is protected by copyright. All rights reserved. 
 
Figure 1: Study flow chart 
R = randomisation, MCh = Methacholine challenge test, BDP/FF = Beclometasone 
dipropionate/formoterol fumarate 
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Figure 2: FEV1 profiles 
P1: baseline value; P2: value at the end of the methacholine challenge test 
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Figure 3: FEV1 time to recovery from methacholine challenge 
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Figure 4: Borg dyspnoea score profiles 
P1: value before the start of the methacholine challenge test; P2: value at the end of the 
methacholine challenge test (baseline) 
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Table 1: Patient baseline demographics. ICS: inhaled corticosteroids, LABA: long-acting beta2-
agonist, SD: standard deviation  
Characteristics Patients (n = 65) 
Male/female 40/25 
Mean Age ± SD, yrs  41.3 ± 10.8  
Non-smokers/ex-smokers 50/15 
Mean FEV1 ± SD, L [% pred] 2.95 ± 0.64 [80.7 ± 11.0] 
Mean FVC ± SD, L [% pred] 4.37 ± 0.86 [97.1 ± 10.2] 
Previous asthma medication 
ICS alone 
ICS/LABA combinations (free or fixed)  
 
40  
25 
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Table 2: FEV1 and Borg dyspnoea evaluation data (ITT population). L: liter; SD: Standard Deviation; 
SE: Standard Error; CI: Confidence Interval; IQR: InterQuartile Range. † Estimated by the Kaplan-
Meier method. For FEV1: comparison BDP/FF DPI vs pMDI, p = 0.554; comparison BPP/FF DPI vs 
placebo, p < 0.0001. For Borg score: comparison BDP/FF DPI vs pMDI, p = 0.609; comparison BPP/FF 
DPI vs placebo, p = 0.042. * p < 0.0001 for superiority testing 
 
 
BDP/FF DPI 
(N = 63) 
BDP/FF pMDI 
(N = 62) 
Placebo 
(N = 63) 
FEV1, L     
Baseline, L: mean ± SD 2.90± 0.62 2.82 ± 0.60 2.83  ± 0.60 
After methacholine: mean ± SD 1.90 ± 0.44 1.86 ± 0.42 1.86 ± 0.40 
Change vs baseline at 5 min post-dose, L    
Adjusted means ± SE -0.51 ± 0.02 -0.51 ± 0.02 -0.73 ± 0.02 
Comparison: difference (95% CI)    
BDP/FF DPI vs BDP/FF pMDI or placebo  0.002 (-0.06; 0.07) 0.22 (0.16; 0.29) * 
BDP/FF pMDI vs placebo  0.22 (0.16; 0.28) *  
Time to recovery, min: median (IQR) † 8.0 (4.5;  16.7) 7.5 (3.50; 17.1) 28.2 (13.3; 38.4) 
Borg dyspnoea score    
Baseline: mean ± SD 0.41 ± 0.80 0.21 ± 0.53 0.30 ± 0.78 
After methacholine: mean ± SD 4.21 ± 1.91 4.12 ± 2.09 4.21 ± 1.94 
Change vs baseline at 5 min post-dose    
Adjusted means ± SE -2.14 ±  0.12 -2.17 ± 0.12 -1.55 ± 0.12 
Comparison: difference (95% CI)    
BDP/FF DPI vs BDP/FF pMDI or placebo  0.02 (-0.32; 0.36) 
-0.599 (-0.94; -
0.26) * 
BDP/FF pMDI vs placebo  -0.62(-0.96; -0.29) *  
Time to recovery, min: median (IQR) † 4.25   (2.50;  10.00) 4 (1.00;  8.75) 
10.00 (3.00; 
20.00) 
 
 
